Matthew D Sims MD PhD, FACP, FIDSA
Director of Infectious Diseases Research, Beaumont Health. Professor, Internal Medicine and Biomedical Sciences, Oakland University William Beaumont School of Medicine
Join to View Full Profile
3535 W. 13 Mile RdSuite 605Royal Oak, MI 48073
Phone+1 248-551-0495
Fax+1 248-551-7268
Dr. Sims is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Rochester Medical CenterFellowship, Infectious Disease, 2003 - 2006
Stony Brook Medicine/University HospitalResidency, Internal Medicine, 2000 - 2003
Stony Brook University Health Sciences Center School of MedicineClass of 2000
Certifications & Licensure
MI State Medical License 2006 - 2025
NY State Medical License 2003 - 2006
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Infectious Disease
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli (OVERCOME) Start of enrollment: 2012 Oct 06
- Study of Debio 1450 for Bacterial Skin Infections Start of enrollment: 2015 May 01
- SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI) Start of enrollment: 2015 May 01
- Join now to see all
Publications & Presentations
PubMed
- From Castaways to Discoveries: Unveiling Treasures in Skin RNAseq Using a Novel Multidimensional Data Processing Workflow Including Infection-Host Dynamics.Disha Bhargava, Alec Labadie, Rebecca L Hanson-Rios-Stutz, Austin Goodyke, Ella M Moses
Physiological Genomics. 2025-03-12 - Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI.Colleen S Kraft, Matthew Sims, Michael Silverman, Thomas J Louie, Paul Feuerstadt
Infectious Diseases and Therapy. 2024-10-01 - Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI.Colleen S Kraft, Matthew Sims, Michael Silverman, Thomas J Louie, Paul Feuerstadt
Infectious Diseases and Therapy. 2024-10-01
Journal Articles
- Effect of Algorithm-Based Therapy vs Usual Care on Clinical Success and Serious Adverse Events in Patients with Staphylococcal BacteremiaIssam Raad, Mark E Rupp, Thomas L Holland, Helen W Boucher, G Ralph Corey, Paul Riska, Deverick J Anderson, Matthew Sims, Dannah Wray, Sara E Cosgrove, Manuela Carugat..., JAMA
Press Mentions
Metro Detroit ERs Seeing More Patients, Longer Waits Amid Flu SeasonFebruary 6th, 2025- What to Know About 'Quad-Demic' of COVID, Flu, RSV and Norovirus in USJanuary 17th, 2025
- How Wayne State Grad and St. Clair Shores Native Helped Create New RSV VaccineMay 5th, 2023
- Join now to see all
Grant Support
- Screening to Prophylax against Clostridium difficile Infection (StoP CDI)Agency for Healthcare Research and Quality2016–2021
Professional Memberships
- Fellow
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
